Hey Market Watcher,

NanoViricides (NYSE: NNVC) is ripping over 10% premarket — and the crowd’s just starting to wake up.

This isn’t hype. This is a tiny biotech with a real shot at becoming the first line of defense against the next pandemic.

Their lead dr.ug, NV-387, just cleared Phase I human trials — and it’s shown powerful preclinical activity against:
 

• The new COVID variant “Nimbus” (NB1.8.1)
• H5N1 bird flu — already infecting U.S. farmworkers
• RSV, MPox, Influenza, and even Measles
   

This isn’t another vaccine. NV‑387 is a direct-acting antiviral that mimics a key human cell receptor viruses use to infect us.

Here’s why it matters:

✅ Viruses can’t easily mutate around it
✅ It works across multiple virus families
✅ It’s ready when the world’s defenses are not

Wall Street’s still behind on this one. You don’t have to be.

The momentum is building. Are you in?

(1)

What Just Dropped: (3)(4)(5)(6)(7)
 

• June 2025: NNVC confirms NV‑387 outperforms Tamiflu®, Remdesivir®, and Xofluza® in preclinical respiratory models
• Phase II trial for MPox launching this year in the DRC (ethics board already approved)
• Measles animal studies are underway, with data expected this summer
• ARI basket trial for COVID, RSV, and Influenza in planning phase
• NNVC’s own Connecticut cGMP facility is making the dr.ug in-house, with scale-up potential
• Company is funded into early 2026, with multiple paths for non-dilutive funding via partnerships or grants
   

Why the Timing Is Perfect (3)(4)(5)(6)(7)
 

Let’s be blunt: This is a microcap with a real shot at going big.

While Big Pharma races to update old vaccines, NNVC has something better: a mutation-resistant antiviral platform. And their execution has been on point:
 

• NV‑387 is through Phase I with a clean safety profile
• MPox Phase II trials begin this year
• Measles—where no antivirals exist—could become their second fast-track
• Bird flu fears are rising fast
• Respiratory viruses are still a $20B+ global market
• And it all runs through one core platform dr.ug
   

But Nobody’s Paying Attention… Yet (3)(4)(5)(6)(7)

Wall Street is still too busy chasing AI stocks and swing trades. NNVC hasn’t hit the spotlight—but it will.

Because the moment any of these things happens—

✅ Strong Measles efficacy data

✅ MPox human trial success

✅ Emergency use for H5N1

✅ Respiratory trial filing

✅ Strategic licensing deal or partnership—

This stock can move… Fast.

And with shares still sitting near $1.30, the setup is asymmetrically attractive.

The Bottom Line

You don’t get many biotech plays like this.

• Real dr.ug.
• Broad coverage.
• Tight execution.
• Viral targets with real urgency.
• Multiple shots on goal.
• Clean manufacturing and funding runway.
   

NanoViricides (NNVC) has all the makings of a real breakout story. 

Don’t be late to this one.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://www.nanoviricides.com/
2. https://finance.yahoo.com/quote/NNVC/
3. https://www.biospace.com/nanoviricides-reports-that-the-phase-i-nv-387-clinical-trial-is-completed-successfully-and-data-lock-is-expected-soon
4. https://www.biospace.com/press-releases/broad-spectrum-antiviral-drug-nv-387-cleared-for-phase-ii-clinical-trial-application-by-the-national-ethics-committee-of-the-democratic-republic-of-congo
5. https://www.biospace.com/press-releases/measles-outbreak-expands-begging-for-a-drug-to-treat-the-infection-nanoviricides-declares-it-is-ready-to-fight-the-outbreak
6.https://www.sec.gov/Archives/edgar/data/1379006/000141057825001336/nnvc-20250331x10q.htm 
7. https://www.proactiveinvestors.co.uk/companies/news/1070900/nanoviricides-wins-ethics-approval-for-phase-ii-mpox-drug-trial-in-drc-1070900.html

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 06/19/2025 and ending on 06/20/2025 (the “Campaign”) to publicly disseminate information about NanoViricides, Inc. (NNVC:US). Momentum Media LLC has been compensated $17,500 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.